Lv8
7640 积分 2023-02-21 加入
Abstract 1733: MP0317, a CD40xFAP targeting multi-specific DARPin® therapeutic, drives immune activation and reverts myeloid-mediated T-cell suppression in vitro and ex vivo
1天前
待审核
Abstract 6782: Discovery of a new class of mutant-targeted catalytic RAS(ON) inhibitors with retained antitumor activity in setting of emergent resistance due to elevated RAS flux
2个月前
已采纳
Abstract 5461: BG-C477, a novel topoisomerase 1 inhibitor-based ADC, exhibits antitumor activity in carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing preclinical models
2个月前
已采纳
Abstract CT039: Results of a first-in-human phase 1 trial of anchored IL-12 drug conjugate (ANK-101)
2个月前
已采纳
Abstract 432: Mechanisms of acquired resistance to ARV-471, a novel PROTAC® estrogen receptor degrader
3个月前
已采纳
Abstract 5001: Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients with resectable squamous cell carcinoma of the head and neck
4个月前
已采纳
Data from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30<sup>+</sup> Malignancies
4个月前
已采纳
Abstract 2826: Celastrol-Cu nanoparticles induce self-amplified cuproptosis augmented cancer immunotherapy
4个月前
已采纳
Abstract CT275: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors
4个月前
已采纳
Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination Strategies
4个月前
已采纳
Discovery of Bis-imidazolecarboxamide Derivatives as Novel, Potent, and Selective TNIK Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis
皖公网安备34019202002308
